These warnings can help you make informed decisions about your treatment and ensure your safety
For patients researching GLP-1 weight loss, medical weight loss, semaglutide, or tirzepatide, the most important question is not simply, Which medication causes the most weight loss? A better question is: Which medically supervised approach is appropriate for my health history, body composition, metabolic risk, side-effect tolerance, and long-term maintenance plan
Adjusting to the injection routine: Since Tirzepatide is administered via a weekly injection, you may need to get accustomed to the injection process
In the right hands, it can achieve results that more significant than what we can do with less invasive treatments
The FDAs warning letters come as the shortage status of Eli Lillys tirzepatidemarketed as Mounjaro for type 2 diabetes and as Zepbound for chronic weight managementremains in limbo, enabling compounding pharmacies to legally continue making versions of the drugs